Jessa Ziekenhuis
- Address
- lock Available on a paid plan
Cardiovascular Diseases at Jessa Ziekenhuis
Clinical research in cardiovascular diseases focuses on acute coronary syndrome and related risks after a heart attack, with the aim of improving protection against major heart and brain events. These studies are designed to evaluate whether adding a new therapy can better reduce serious complications and support standard care.
- Reducing the risk of major cardiovascular events such as heart-related death, heart attack, and ischemic stroke
- Testing a new treatment approach for patients recovering after a myocardial infarction
The work at this hospital brings together a broad investigator team to explore better ways to prevent recurrent cardiovascular problems and improve long-term outcomes for patients.
Neoplasms and Oncology Research
The oncology program at Jessa Ziekenhuis includes studies in neoplasms, especially colon cancer after surgery. The trials are aimed at understanding whether an established medicine can help improve survival and lower the chance of cancer returning in patients with resected disease.
- Evaluating ways to improve overall survival in stage II and III colon cancer
- Studying recurrence prevention after surgical treatment of colon carcinoma
This research reflects a practical focus on strengthening post-treatment care and finding better supportive strategies for patients with colorectal cancer.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 18 therapeutic areas and 15 of 264 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 258 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 52 by active trials.
- 1F. Hoffmann-La Roche AG6active
lock +51 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1F. Hoffmann-La Roche AG14trials
lock +30 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 307 other sites in Belgium
Therapeutic Area Benchmark — Belgium
Select a therapeutic area to compare against other sites in Belgium.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Belgium
Market Share
Country: Belgium
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Jessa Ziekenhuis
lock Showing 1 of 168 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (21492 ARASTEP) A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical recurrence (BCR) of prostate cancer | Bayer AG, Bayer Consumer Care AG | Phase III | Not Recruiting | Oct 2023 | — |
IMP list
lock Showing 1 of 264 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 28 | Unknown | 2018-09-11 | 2025-11-18 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.